- Home
- Products
- Customized ADCs
- PCSK9
- Anti-PCSK9 (Bococizumab)-MC-MMAF ADC
Anti-PCSK9 (Bococizumab)-MC-MMAF ADC (CAT#: ADC-W-2230)
This ADC product is comprised of an anti-PCSK9 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- PCSK9
- Alternative Names
- PCSK9; proprotein convertase subtilisin/kexin type 9; HCHOLA3, hypercholesterolemia, autosomal dominant 3; FH3; NARC 1; NARC1; NARC-1; HCHOLA3;
- Target Entrez Gene ID
- 255738
- Target UniProt ID
- Q8NBP7
- Overview
- This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants.
- Overview
- Humanized Anti-PCSK9 IgG2-kappa antibody, Bococizumab
- Generic name
- Bococizumab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-FGFR2-sulfo-SMCC-DM1 ADC-7 (CAT#: ADC-W-057)
- Anti-TMEFF2-Mc-VC-PABC-MMAE ADC-1 (CAT#: ADC-W-089)
- Anti-RSV (Felvizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2004)
- Anti-SLC39A6-VC-MMAE ADC-1 (CAT#: ADC-W-425)
- Anti-HBV (Exbivirumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2077)
- Anti-TNFRSF10A (Mapatumumab)-SMCC-DM1 ADC (CAT#: ADC-W-2414)
- Anti-ERBB2 (Margetuximab)-SMCC-DM1 ADC (CAT#: ADC-W-1106)
- Anti-Robo4-SPDB-DM4 ADC (CAT#: ADC-W-214)
- Anti-RSV F (Motavizumab)-MC-MMAF ADC (CAT#: ADC-W-2146)
- Anti-CD22 (Bectumomab)-MC-MMAF ADC (CAT#: ADC-W-796)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2230. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2231 | Anti-PCSK9 (Bococizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2379 | Anti-PCSK9 (Evolocumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2383 | Anti-PCSK9 (Evolocumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2315 | Anti-PCSK9 (Ralpancizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2232 | Anti-PCSK9 (Bococizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-485 | Anti-EphA2-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-518 | Anti-TM4SF1-Mc-LP2 ADC-2 | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| ADC-W-517 | Anti-TM4SF1-Mc-LP2 ADC-1 | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2579 | Anti-CEACAM5-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-063 | Anti-HIgG(Fab)-N-MMAF ADC | Noncleavable linkers | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
